According to the Complaint, AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The Complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) AbbVie’s strategy to increase the sales growth of its blockbuster drug, HUMIRA, was through illegal kickbacks and unlawful sales and marketing tactics; (2) such practices would lead to heightened scrutiny by State governments and agencies; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

This case was voluntarily dismissed on November 21, 2018. A related case continues in the Northern District of Illinois under Docket 18-CV-06790.

On May 13, 2019, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed a consolidated Complaint on July 22. Defendants filed a Motion to Dismiss the consolidated Complaint on September 20. On September 1, 2020, the Court issued an Order denying Defendants' Motion to Dismiss.

Plaintiff filed a Motion for Class Certification on February 1, 2021. On September 23, the Court issued an Order granting the Motion for Class Certification.

On March 8, 2022, the Court issued an Order appointing a co-class Representative.